Overview
Mirella Mashiach is a co-founder at Output Biosciences [1][3]. Mashiach has held positions in pharmaceutical business development, intellectual property law, and venture capital [5][6][7][8][4]. At Teva Pharmaceuticals, Mashiach served as Vice President of Business Development and Strategy from 2010 to 2015 [5]. Mashiach founded Mesia Ventures in 2016 and continues as a Founding Partner [4]. Mashiach's background in biotech identified limitations in drug development processes, including the inability to understand whole biological systems and the high failure rates and costs of traditional development [2]. Mashiach attended Y Combinator's S21 cohort [9] and holds a Master of Arts in Philosophy from Tel Aviv University [10] and a Bachelor of Science in Computer Science from Tel Aviv University [11].
Profile introduction
As a veteran of the Bio industry, I've managed, funded, and headed dozens of strategic partnerships and investments. Through this experience, I saw many of the limitations of biotech drug development: the focus on only discrete pieces of the puzzle because of inability to understand whole biological systems, and how this limits our ability to create effective therapies; the lengthy and expensive drug development process, that ends in a binary failure/success (mostly failure); and the adverse impact on patients, who are left with either no treatment options or ones with limited efficacy and saf…
Career history
- Co-FounderJul 2021 to presentOutput Biosciences
- Founding Partner2016 to presentMesia Ventures
- Vice President, Business Development & Strategy2010 to 2015Teva Pharmaceuticals
- Attorney2003 to 2009SNR Denton
- Counsel2001 to 2003Lumenis
- Intellectual Property Lawyer and Patent Attorney1998 to 2001Eitan, Pearl, Latzer & Cohen Zedek
Education
S212021Y Combinator
Master of Arts (MA), Philosophy2009 - 2011Tel Aviv University
This page shows public professional information only, each fact cited. Is this you? send a correction, or ask for removal within 24 hours, no questions asked.